Ladarixin

Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin can be used for the research of COPD and asthma[1].

Product Specifications

CAS Number

[849776-05-2]

Product Name Alternative

DF 2156A (free base)

UNSPSC

12352005

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ladarixin.html

Purity

99.71

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C(F)(F)F)(OC1=CC=C([C@@H](C)C(NS(=O)(C)=O)=O)C=C1)=O

Molecular Formula

C11H12F3NO6S2

Molecular Weight

375.34

References & Citations

[1]Matheus Silverio Mattos, et al. CXCR1 and CXCR2 Inhibition by Ladarixin Improves Neutrophil-Dependent Airway Inflammation in Mice. Front Immunol. 2020 Oct 2;11:566953.|[2]Daria Marley Kemp, et al. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 2017 Feb 28;8 (9) :14428-14442